The Current Situation on Major Depressive Disorder in China: Research on Mechanisms and Clinical Practice

详细信息    查看全文

• 作者：Zhenghua Hou ; Wenhao Jiang ; Yingying Yin ; Zhijun Zhang…
• 刊名：Neuroscience Bulletin
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：32
• 期：4
• 页码：389-397
• 全文大小：627 KB
• 刊物主题：Neurosciences; Human Physiology; Anesthesiology; Anatomy; Neurology; Pain Medicine;
• 出版者：Springer Berlin Heidelberg
• ISSN：1995-8218
• 卷排序：32

文摘

Depression is the most disabling disorder worldwide that accounts for the highest proportion of global burden attributable to mental disorders. Major depressive disorder (MDD) is characterized by deep sadness, reduced energy, vegetative nervous system dysregulation, cognitive dysfunction, and even a high suicidal tendency. Although other treatment choices are available, antidepressant medication is the front-line treatment option for MDD. Regarding clinical efficacy, only ~50% of patients respond to frontline antidepressants, and <33% obtain remission. Currently, objective indexes to guide clinical decisions are still lacking. Furthermore, knowledge about the neurobiological mechanisms underlying discrepant antidepressant outcomes is still also fragmentary. In the present review, we discuss the current research progress and clinical opinions on MDD in China.KeywordsMajor depressive disorderEpidemiologyAntidepressantPathogenesisBiomarkerChina